Medpace Holdings, Inc.
MEDP

NASDAQ > Medical - Diagnostics & Research
DCF:$454.25  |  
$5.30(1.57%)
EPS: $10.63
Rating:
Price: $337.75 USD
Market Cap: $10.64B

...Loading MEDP Peers...





Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

    5800 Employees

    CEO : Dr. August James Troendle M.D.

    Address : 5375 Medpace Way, Cincinnati,OH, US, - 45227,

Key ExcutivesDesignation
Ms. Lauren MorrisAssociate Director of Investors Relations
Mr. Stephen P. Ewald J.D.Chief Compliance Officer, General Counsel & Corporate Secretary
Mr. Jesse J. Geiger BBA, CPAPresident
Mr. Kevin M. BradyChief Financial Officer & Treasurer
Ms. Susan E. Burwig BSN, MAExecutive Vice President of Operations
Brandon EbkenChief Information Officer
Mr. Todd MeyersVice President of Business Development & Marketing
John T. Wynne MBASenior Vice President of Commercial Operations & Clinical Pharmacology Unit
Mr. Reinilde Heyrman M.D.Chief Medical Officer of Medical Department
Dr. August James Troendle M.D.Chairman & Chief Executive Officer